TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04795336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 mg
Description: Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 mg
Description: Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.
Study: NCT05761717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
Description: Subcutaneous Injection
Study: NCT06471283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Exercising physical activity during dialysis
Study: NCT06466018

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Schirmer test paper
Description: This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved.
Study: NCT06303609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nonablative radiofrequency
Description: The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the electrode. There will be a gradual increase in temperature, monitored by a digital infrared thermometer, to reach temperature between 36°C and 38°C, keeping the movement for two minutes in each area, spending in total around 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal dilator
Description: Both groups will use the vaginal dilator at the end of each session for 15 minutes and all patients will be advised to use it for 15 minutes daily in a home based treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal dilator
Description: Both groups will use the vaginal dilator at the end of each session for 15 minutes and all patients will be advised to use it for 15 minutes daily in a home based treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham nonablative radiofrequency
Description: The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the active electrode. As the device will not deliver the radiofrequency wave, the gel will be heated so the patient has the feeling of the temperature change, keeping the movement for two minutes in each area, spending in total around 10 minutes.
Study: NCT04991298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral premedication
Description: Oral anesthesia premedication for congenital Cardiac surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral premedication
Description: Oral anesthesia premedication for congenital Cardiac surgery
Study: NCT05090293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Lifestyle Intervention with Body Image Treatment (LIBI)
Description: A body image protocol designed to improve outcomes in a group-delivered multidisciplinary weight loss program by addressing body acceptance within a context of positive behavior change and utilizing existing body discomfort and re-purposing it as an agent of motivation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention (LI)
Description: A multidisciplinary, group-delivered, multidisciplinary weight loss program addressing various lifestyle factors impacting weight loss.
Study: NCT01207622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06466018

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Schirmer test paper
Description: This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Schirmer test paper
Description: This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved.
Study: NCT04988360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMD: Immersive VR
Description: Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMD: Immersive VR
Description: Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet: Non-immersive VR
Description: Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet: Non-immersive VR
Description: Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.
Study: NCT04331743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-entrapped Mitoxantrone Hydrochloride Injection
Description: Intravenous infusion
Study: NCT04797624

Intervention type: PROCEDURE
Intervention: Gastric cancer surgery
Description: Appropriate gastric cancer surgery types for the convenient patients

Intervention type: PROCEDURE
Intervention: Gastric cancer surgery
Description: Appropriate gastric cancer surgery types for the convenient patients
Study: NCT06455046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: PD-1/CTLA-4 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus 5 Injection
Description: Recombinant Human Adenovirus 5 Injection
Study: NCT06141356

Intervention type: DRUG
Intervention: [18F]Florbetazine ([18F]92)
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.

Intervention type: DRUG
Intervention: [18F]Florbetazine ([18F]92)
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.

Intervention type: DRUG
Intervention: [11C]PIB
Description: Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.

Intervention type: DRUG
Intervention: [11C]PIB
Description: Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.
Study: NCT05331859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: autologous serum (AS)
Description: Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional
Description: Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
Study: NCT05366400

Intervention type: DIAGNOSTIC_TEST
Intervention: ECHO
Description: Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.

Intervention type: DIAGNOSTIC_TEST
Intervention: ECHO
Description: Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
Study: NCT05173116

Intervention type: OTHER
Intervention: Medical Outcomes Study Short Form 36 (SF 36)
Description: completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).

Intervention type: OTHER
Intervention: observationnal study
Description: data collection
Study: NCT04448028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20mg
Description: Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole 20mg
Description: Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
Study: NCT05328557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUG252
Description: CUG252 will be administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by subcutaneous (SC) injection
Study: NCT06319950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib, 160mg po qd
Study: NCT06205849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRE + intratumoral mitazalimab (CD40 antibody) injection
Description: Surgical IRE will be performed using the NanoKnife System with intraoperative ultrasound guidance via laparotomy under general anesthesia. Mitazalimab (CD40 antibody) will be administered 5 minutes after completion of IRE by slow injection into the center of the ablated zone using a small needle. Core needle biopsies of the tumor will be obtained immediately prior to IRE for identification of candidate tumor antigens. Peripheral blood will be obtained immediately prior to and 12 weeks after the study intervention for analysis of systemic immune effects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Description: Non-thermal tumor ablation using short pulses of high voltage electrical current delivered using 19-gauge needles placed via laparotomy using ultrasound guidance
Study: NCT05112783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Henan Tuoren Endotracheal Tube
Description: The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smiths Portex Tracheal Tubes
Description: The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
Study: NCT05122637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RapidPulseTM Aspiration System
Description: The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care Aspiration Thrombectomy System
Description: Commercially available aspiration catheter with commercially available aspiration pump
Study: NCT05254028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: filiform needle
Description: Manual acupuncture using filiform needles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: filiform needle
Description: Manual acupuncture using filiform needles
Study: NCT05125250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Group
Description: will received treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Group
Description: will receive vestibular exercises which comprises of postural awareness training, balance board exercises, Foveal vision exercises .
Study: NCT05155254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO102-IO103
Description: IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously
Study: NCT06205108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS stimulation
Description: Non-invasive stimulation of the auricular branch of the vagus nerve (cymba conchae). Research device from tVNS technologies.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Non-invasive stimulation of the ear lob (not innervated by the vagus nerve). Research device from tVNS technologies.
Study: NCT06319950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib，80mg po qd
Study: NCT05358613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Choices
Description: The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller \& Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Choices
Description: The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller \& Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion.
Study: NCT04790565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal microbiota in frozen capsules
Study: NCT05901753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryseal pro supra glottic device
Description: The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway- Proseal™
Description: The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.
Study: NCT03946696

Intervention type: OTHER
Intervention: Interactions with therapy-animals
Description: How people interact with humans and non-humans animals during and outside visits from therapy-animal teams.
Study: NCT05598255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: During standard anaesthetic management: IV administration of dexamethasone (0,5mg/kg, with a maximum dose of 5mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: During standard anaesthetic management: IV administration of dexamethasone (0,5mg/kg, with a maximum dose of 5mg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudale Blockade with levobupivacaine
Description: Administration of levobupivacaine 0,25%0,5ml/kg through the hiatus sacralis lege artis, before incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal penile nerve block with levobupivacaine
Description: Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia, before incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal penile nerve block with levobupivacaine
Description: Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia, before incision.